Zug (ots) - AmVac AG announces today that the EU has approved two grant applications under the seventh framework programme (FP7) for the development of innovative vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with leading expertise in vaccine design and development. Total funding for all participating partners is approximately EUR 6 ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
Schlieren-Zurich, Switzerland (ots) - Prionics, a world leader in farm animal diagnostics, has entered into a strategic partnership with the Belgian company Bio-X Diagnostics to make their innovative diagnostic solutions available to global markets. The collaboration will include distribution, product development and production. Through this partnership, Prionics and Bio-X Diagnostics customers will profit from an ...
Lugano, Switzerland and Woodcliff Lake, NJ, USA (ots) - Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and ...
Lugano/Glattbrugg, Switzerland (ots) - Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of ...
Basel/Milan (ots) - On Saturday April 20, Italian animal rights extremists invaded laboratories at the University of Milan and the associated National Institute of Neurosciences to destroy a large number of important research projects. On behalf of more than 6000 researchers worldwide, the Basel Declaration condemns ...
Lugano, Switzerland/Raleigh, N.C. (ots) - The Swiss pharmaceutical Helsinn Group, a leading player in the cancer supportive care arena, announced today that DARA BioSciences, Inc., a U.S. specialty pharmaceutical company focused on oncology and oncology supportive care products, has launched Gelclair® into the U.S. ...
Lugano, Switzerland (ots) - Helsinn Group has entered into a new partnership with Healthcare Businesswomen's Association (HBA). HBA is the premier catalyst for the leadership development of women, to further the advancement and impact of women in healthcare worldwide. HBA accomplishes this by providing educational opportunities to develop cutting-edge industry ...
Zug (ots) - AmVac AG announces new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate as the most promising for further development among a range of potential leads. In preclinical studies, renowned RSV expert Prof.ssa Grazia Cusi and her team at the University of Siena, Italy, have now confirmed the ...
Norderstedt (ots) - Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has announced it has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of global healthcare company Sysmex Corporation. Sysmex has the exclusive right to provide sales and support for Endomagnetics' SentiMag® system across the EMEA region. This is Endomagnetics' first ...
Paris, France (ots) - - Data presented at ATTD by Sanofi will focus on the company's integrated portfolio of therapeutic solutions, blood glucose monitoring, insulin delivery and contributions to advancing diabetes research - Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its comprehensive portfolio of ...
Lugano, Switzerland and Mexico City, Mexico (ots) - Stendhal strengthens its pipeline of in-licensed specialty drug products by signing a Distribution and License Agreement with Helsinn Group for an innovative phase III ghrelin receptor agonist. Swiss pharmaceutical Helsinn Group has granted Latin American specialty ...
Lugano (ots) - Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will present an overview of the Helsinn group, its products and corporate goals at the 31st Annual J.P. Morgan Healthcare Conference, San Francisco. Dr. Braglia's presentation will be ...
Schlieren-Zurich (ots) - The European Food Safety Authority (EFSA) has reviewed field performance data of the BOVIGAM® Interferon-y (IFN-y) test and recommends IFN-y tests for inclusion in the official list of stand-alone tests for bovine tuberculosis (TB). BOVIGAM® is currently widely used as a supplementary test to complement skin testing. Prionics trusts that the ...
Lugano, Switzerland (ots) - The Swiss pharmaceutical Helsinn Group announces today that Taiho Pharmaceutical Co. Ltd., Japanese licensee of Helsinn's second generation 5-HT3 receptor antagonist (5- HT3 RA) palonosetron, has launched on the national market the 0.75mg infusion bag formulation of palonosetron hydrochloride (Aloxi®). The infusion bag is an additional formulation to the 0.75mg injectable form already marketed ...
Schlieren-Zurich (ots) - An innovative new test is now available to detect TSE (scrapie and mad cow disease) in sheep and goats. With the Prionics®-Check PrioSTRIP SR, Prionics brings to the market the first test to achieve high diagnostic sensitivity on preclinical TSE cases. The test was approved today by the European Commission for use in TSE testing in small ...
Lugano (ots) - Helsinn Group announces that it has signed an agreement with the Conquer Cancer Foundation of the American Society of Clinical Oncology to provide long-term financial support for CancerLinQ, a multi-phase initiative to build a rapid learning system in oncology. Helsinn supports the Foundation's ...
Ittigen, Switzerland (ots) - Pevion Biotech AG today announced the launch of a new program called Defensomes, a platform for broad spectrum immune enhancement via mechanisms of innate immunity. The proprietary technology is derived from a vaccine platform with a solid safety track record comprising more than 80 ...
Zurich, Switzerland (ots) - Sequana Medical is pleased to announce that it has received CE mark approval for use of its alfapump® system in patients with ascites caused by cancer (malignant ascites). The alfapump® system was first introduced to the European market last year for patients with refractory ascites ...
Zug (ots) - AmVac AG has announced that it has made decisive progress in the development of their new RSV vaccine. The vaccine candidate is based on AmVac's innovative Sendai virus vector platform and developed for the prevention of respiratory infections, which are induced by RSV (respiratory syncytial virus). RSV ...
Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce that BINOSTO (TM) (alendronate sodium) Effervescent Tablet for buffered oral solution (70 mg) is now available by prescription in the United States. The U.S. Food and Drug Administration earlier this year approved BINOSTO to treat ...
Lugano, Switzerland and Melbourne, Australia (ots) - Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist Melbourne biopharmaceutical company Specialised Therapeutics ...
Lugano, Switzerland & Vienna, Austria (ots) - New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile The oral formulation of palonosetron, the second generation 5-HT3 receptor ...
Freienbach, Switzerland (ots) - EffRx Pharmaceuticals SA is proud to announce and welcome Lorenzo Bosisio, new Head of Business Development and Marketing. Lorenzo will be responsible for the outlicensing and marketing of EffRx's approved product Steovess®/BinostoTM outside of the USA and Canada as well as developing the business for EffRx's other pipeline products. ...
Lugano (ots) - Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn's new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV). The agreement covers the exclusive license and distribution rights for a ...
Lugano, Switzerland / Raleigh, N.C., USA (ots) - Gelclair® Strengthens DARA's Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S. ...
Lugano, Switzerland (ots) - Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme Through its support to the Sharing Progress in Cancer Care (SPCC) Programme, Helsinn Group starts to actively collaborate with the European School of Oncology (ESO) in promoting education in oncology, with special attention to cancer supportive care. SPPC is a collaborative ...
Munich (ots) - Jan Van Ruymbeke, 53, will become the new Chief Executive Officer of Daiichi Sankyo Europe this autumn. The native of Belgium will replace Reinhard Bauer, who is retiring after 10 years in this position. Van Ruymbeke will assume responsibility for the pharmaceutical company in October. Until the end ...
Oss, The Netherlands (ots) - Movianto Nederland, the logistics and transportation company specialised in pharmaceuticals and healthcare, is set to begin operations in the new state-of-the- art warehouse especially built to meet the clients' needs. The strategically located warehouse also offers the largest facility for the storage of deep frozen pharmaceutical products ...